Who we are
We are a quality-driven ISO 13485:2016 Certified Manufacturer and formulator of advanced media and biopreservation solutions to serve and advance the fields of cell therapy, gene therapy and regenerative medicines.
Our manufacturing experience, attention to detail and proven operational excellence ensures that we produce consistent batch to batch quality of all of our custom and standard solutions. This allows us to provide our customers with the highest quality and ready to use solutions to support their needs.
Our mission is to serve as a reliable and timely strategic partner to support research, pre-clinical and clinical activities through our custom manufacturing services and our innovative culture medium & biopreservation solutions.
Contact us
Developing the Next Generation of BioPreservation Media
Our goal is to leverage our expertise in the cryopreservation of cells in the human assisted reproductive technology (ART) market and bring together a team of expert cryobiologists to formulate and develop innovative cryopreservation solutions. Our aim being to improve the shelf-life and post-preservation cell viability of cryopreserved cells, leading to more successful outcomes in our customers’ research and clinical studies.
Proven, Reliable Manufacturer of BioSolutions
We have a history and proven success of manufacturing high quality, consistent culture medias and cryopreservation solutions, including custom manufacturing in accordance with the highest regulatory standards across the globe.
CaseBioscience adheres rigorously to cGMP guidelines to ensure consistent, high quality products produced under strict regulatory guidelines. cGMP refers to the Current Good Manufacturing Practice regulations enforced by the US Food and Drug Administration (FDA). It is a system put in place to ensure the proper design, monitoring and control of manufacturing processes and facilities.
Services
Quality driven cGMP manufacturer of leading bioproduction tools and services used to facilitate basic and applied research and drive the commercialization of new cell and gene therapies
